SI-BONE(US:SIBN)2026-02-23 22:32Financial Data and Key Metrics Changes - The company generated record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][20] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [20] - The company achieved its first full year of positive adjusted EBITDA with a 9% adjusted EBITDA margin in the fourth quarter [7][23] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22] Business Line Data and Key Metrics Changes - The number of U.S. physicians using the company's technologies increased by 22% in 2025, with nearly 22,000 procedures performed [6][20] - The company launched the INTRA Ti product, expected to enhance procedural efficiency in SI joint fusion [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [20] - The company expects to commercialize TNT in international markets in late 2026, ahead of the previously planned launch in 2027 [21] Company Strategy and Development Direction - The company is focused on an innovation-led growth strategy, with plans for a series of new product launches targeting new clinical adjacencies [4][8] - The partnership with Smith+Nephew aims to expand access to trauma solutions and enhance market penetration [30][31] - The company is positioned to lead in the sacropelvic space, addressing unmet needs for patients with compromised bone [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the business, supported by a robust pipeline of innovative products and expanding market opportunities [28] - The company anticipates worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [53] Other Important Information - The company ended 2025 with $147.8 million in cash and equivalents, marking a significant improvement in cash consumption compared to 2024 [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][66] Q&A Session Summary Question: How did the Smith+Nephew partnership come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and enhance productivity [30][31] Question: Will the clinical data showing similar outcomes for IPM physicians help create more engagement? - Management confirmed that the INTRA Ti product is designed to cater to interventional spine physicians, enhancing engagement and procedural efficiency [32][34] Question: Can you clarify the guidance for adjusted EBITDA in 2026? - Management indicated that while they expect an increase in adjusted EBITDA, it would be slightly below $20 million [44] Question: What is the expected impact of the INTRA Ti product on the ASC market? - Management noted that INTRA Ti is expected to drive growth in the ASC market, providing a non-allograft solution that aligns with interventional spine physicians' workflows [46][62] Question: What are the drivers behind the gross margin guidance of 78%? - Management explained that the guidance reflects a mix of factors, including product launches and operational initiatives aimed at maintaining profitability [74][76]